Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEIGHTEN: Ticagrelor for High On-Treatment Platelet Reactivity
NCT01869309Phase 4Unknown
- Sponsor
- LifeBridge Health
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by LifeBridge Health. Primary endpoint: Vasodilator Stimulated Phosphoprotein-Phosphorylation at 14 days. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01869309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01869309.